Actively Recruiting
Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes
Led by University of Adelaide · Updated on 2025-12-26
8
Participants Needed
1
Research Sites
48 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The intervention in this study consists of a 75-min intraduodenal infusion of an isotonic solution containing either of calcium chloride (CaCl2) or control (saline). Participants enrolled into the study will receive, in randomised, double-blind fashion (i) Saline (control), (ii) 500 mg CaCl2, or (iii) 1000 mg CaCl2 in three separate sessions, each of which will be separated by at least 4 (and up to 10) days. Each study session will be 4-6 hours. Studies will be carried out in the Clinical Research Facility of the Adelaide Medical School, the University of Adelaide, by staff and students trained in the required techniques.
CONDITIONS
Official Title
Effects of Calcium on Gut Functions and Blood Glucose in Humans With Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male with type 2 diabetes diagnosed by WHO criteria
- Body mass index between 28 and 38 kg/m²
- HbA1c between 6.5% and 7.9% at screening
- Able to withhold blood glucose medications for 48 hours before each study day
- Stable weight with less than 5% fluctuation in the last 3 months
You will not qualify if you...
- Significant gastrointestinal symptoms or history of gastrointestinal disease or surgery
- Current gallbladder or pancreatic disease
- Cardiovascular or respiratory diseases
- Any other illnesses except type 2 diabetes as judged by the investigator
- Use of medications or supplements affecting metabolism, gastrointestinal function, body weight, or appetite
- Lactose intolerance or other food allergies
- Low ferritin levels (<30 ng/mL) or recent blood donation within 12 weeks
- High performance athlete
- Consuming more than 2 standard alcoholic drinks on more than 5 days per week
- Current tobacco smoker or use of recreational drugs
- Vegetarian diet
- Unable to tolerate nasoduodenal tube placement
- Unable to understand the study protocol
- HbA1c below 6% or above 7.9%
- Estimated kidney filtration rate below 45 ml/min
- Unable to withhold medication for 48 hours due to medical reasons
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Clinical Research Facility, Adelaide Health and Medical Sciences Building
Adelaide, South Australia, Australia, 5005
Actively Recruiting
Research Team
P
Prof Christine Feinle-Bisset
CONTACT
P
Penelope Fitzgerald, MsC
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
OTHER
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here